88-91-5 Usage
General Description
4-CHLORO-3,5-DINITROBENZENESULFONIC ACID, also known as CDNSA, is a chemical compound with the molecular formula C6H3ClN2O7S. It is a yellow to orange crystalline powder that is commonly used as a reagent in the chemical industry. CDNSA is a strong sulfonating agent and is often used in the production of dyes, pharmaceuticals, and other organic compounds. It is also used in analytical chemistry as a reagent for the determination of amino acids, proteins, and peptides. Additionally, CDNSA has been investigated for its potential use in the treatment of certain diseases and disorders. However, it is important to handle this compound with care, as it is toxic and can cause irritation to the skin, eyes, and respiratory system.
Check Digit Verification of cas no
The CAS Registry Mumber 88-91-5 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 8 and 8 respectively; the second part has 2 digits, 9 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 88-91:
(4*8)+(3*8)+(2*9)+(1*1)=75
75 % 10 = 5
So 88-91-5 is a valid CAS Registry Number.
InChI:InChI=1/C6H3ClN2O7S/c7-6-4(8(10)11)1-3(17(14,15)16)2-5(6)9(12)13/h1-2H,(H,14,15,16)
88-91-5Relevant articles and documents
Construction of phenoxazine rings containing nitro and sulfonic acid groups leading to phenoxazine-3-sulfonamide derivatives: Their evaluation as novel and potential insulin secretagogues
Reddy, Seelam Venkata,Rao, Gangula Mohan,Kumar, Baru Vijaya,Reddy, Koppela Naresh,Sravya, Konda,Goverdhan, Puchchakayala,Rathore, Vandana,Deora, Girdhar Singh,Pal, Manojit
, p. 587 - 592 (2014)
A series of N-(alkyl/aryl/heteroaryl)-1-nitro-10H-phenoxazine-3- sulfonamides was designed, synthesized and evaluated for its hypoglycemic, hyperglycemic and oral anti-diabetic activities. These compounds were prepared via the construction of a phenoxazine ring containing nitro and sulfonic acid groups in a single step followed by further transformations. One of these compounds exhibited promising anti-diabetic activities comparable to glibenclamide and increased serum insulin levels indicating its potential as a novel insulin secretagogue. This journal is the Partner Organisations 2014.
